{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:58:31Z","timestamp":1791115111140,"version":"4.1.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T00:00:00Z","timestamp":1166572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0000018","type":"journal-article","created":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T19:02:59Z","timestamp":1166641379000},"page":"e18","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":203,"title":["Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F"],"prefix":"10.1371","volume":"1","author":[{"given":"Virginia M.","family":"Zaleskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lazarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2006,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative disorders.","volume":"6","author":"W Dameshek","year":"1951","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2004.12.004","article-title":"Focus on myeloproliferative diseases and myelodysplastic syndromes.","volume":"6","author":"RA Van Etten","year":"2004","journal-title":"Cancer Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210<italic> <sup>bcr\/abl<\/sup> <\/italic> gene of the Philadelphia chromosome.","volume":"247","author":"GQ Daley","year":"1990","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management.","volume":"100","author":"JL Spivak","year":"2002","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera.","volume":"290","author":"JF Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V83.1.99.99","article-title":"Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium.","volume":"83","author":"PN Correa","year":"1994","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.","volume":"95","author":"S Temerinac","year":"2000","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.","volume":"338","author":"AR Moliterno","year":"1998","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1182\/blood-2003-04-1308","article-title":"PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells.","volume":"102","author":"MJ Xu","year":"2003","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"E Parganas","year":"1998","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.","volume":"32","author":"V Ugo","year":"2004","journal-title":"Exp Hematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"AV Jones","year":"2005","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes.","volume":"106","author":"DP Steensma","year":"2005","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.","volume":"106","author":"LM Scott","year":"2005","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow.","volume":"92","author":"WS Pear","year":"1998","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","article-title":"Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.","volume":"5","author":"S Roumiantsev","year":"2004","journal-title":"Cancer Cell"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.185.9.1661","article-title":"Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn.","volume":"185","author":"F Meng","year":"1997","journal-title":"J Exp Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.193.8.925","article-title":"Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant.","volume":"193","author":"JS Friedman","year":"2001","journal-title":"J Exp Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"13336","DOI":"10.1073\/pnas.96.23.13336","article-title":"Increased thrombin responsiveness in platelets from mice lacking glycoprotein V.","volume":"96","author":"V Ramakrishnan","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V89.2.483","article-title":"Thrombopoietin signal transduction in purified murine megakaryocytes.","volume":"89","author":"JG Drachman","year":"1997","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood-2004-09-3534","article-title":"PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.","volume":"105","author":"NC Wolff","year":"2005","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref28","first-page":"146","article-title":"Turning cells red: signal transduction mediated by erythropoietin.","volume":"15","author":"TD Richmond","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for <italic>BCR-ABL1<\/italic>-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.","volume":"36","author":"Y Hu","year":"2004","journal-title":"Nat Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.onc.1208199","article-title":"Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis.","volume":"24","author":"E Ingley","year":"2005","journal-title":"Oncogene"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","article-title":"Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.","volume":"107","author":"AV Jones","year":"2005","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0960-894X(02)00106-3","article-title":"Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.","volume":"12","author":"JE Thompson","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/379645a0","article-title":"Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.","volume":"379","author":"N Meydan","year":"1996","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera.","volume":"280","author":"R Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"ref35","first-page":"253","article-title":"Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.","volume":"125","author":"PJ Campbell","year":"2006","journal-title":"Methods Mol Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.","volume":"102","author":"X Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.","volume":"107","author":"G Wernig","year":"2006","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"C Lacout","year":"2006","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2005.05683.x","article-title":"The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.","volume":"130","author":"H Cario","year":"2005","journal-title":"Br J Haematol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.","volume":"108","author":"C Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.","volume":"106","author":"A Tefferi","year":"2006","journal-title":"Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"RL Levine","year":"2006","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"PJ Campbell","year":"2005","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","volume":"107","author":"PJ Campbell","year":"2006","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood.V93.7.2143","article-title":"Seed versus soil: the importance of the target cell for transgenic models of human leukemias.","volume":"93","author":"P Westervelt","year":"1999","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66","author":"MM Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V98.12.3261","article-title":"Ineffective erythropoiesis in Stat5a(\u2212\/\u2212)5b(\u2212\/\u2212) mice due to decreased survival of early erythroblasts.","volume":"98","author":"M Socolovsky","year":"2001","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl.","volume":"21","author":"S Xie","year":"2002","journal-title":"Oncogene"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0000018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T13:58:17Z","timestamp":1587304697000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0000018"}},"subtitle":[],"editor":[{"given":"Charles","family":"Sawyers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,12,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0000018","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,20]]}}}